ICH Q7 clause 17: Agents, brokers, traders, distributors, repackers, and relabellers

The full supply chain from manufacturer to final user must comply with GMP. This prevents 'quality laundering' where materials of questionable origin are legitimized by intermediaries. Each party handling the API must maintain quality standards appropriate to their operations: simple distributors focus on storage, transport, and traceability; repackers and relabellers have more extensive obligations similar to manufacturers.

Distribution-only activities have focused GMP requirements: controlled storage (temperature, humidity, security), controlled transport (compatible vehicles, qualified carriers), traceability records (receiving, shipping, customer lists), complaint handling and notification back to manufacturer. Full manufacturing GMP (testing, validation, batch records) doesn't apply to pure distributors. Risk-based scaling of requirements is appropriate.

Full traceability is critical for recall capability and quality investigation. Each party must retain: source information (previous party, date received, quantity, original manufacturer), destination information (next party, date shipped, quantity), batch information throughout. If an intermediary re-packages, the linkage from new batch number to original batch must be documented. Gaps in traceability are a serious quality system failure.

Even distribution-focused parties need quality systems. Required elements: written procedures for key activities, training of personnel, documentation and records, complaint handling, change control, deviation management, management review. The system's scope should match the operations — a simple distributor has simpler requirements than a repacker performing more manipulation. Quality systems should be documented and periodically reviewed for effectiveness.

Repackaging and relabelling create the same risks as manufacturing: contamination, mix-ups, identity errors. Controls must match these risks: clean facilities with environmental controls, written procedures, trained personnel, segregation of products, pre-operation cleaning, reconciliation of packaging/labels. Repacking operations for APIs intended for sterile drug products have additional requirements (aseptic controls).

Repacker batch numbers must enable reverse traceability to the original manufacturing batch. Common approaches: include the original batch number in the repacker's batch number (e.g., 'REPACK-MFG123'), maintain a cross-reference database, or include the original batch number in records accompanying each repack. The original CoA must be retained and available — often a copy accompanies the repacker's CoA to the next recipient.

Changing the container can affect stability (different barrier properties, different extractables, different moisture transmission). The repacker must generate stability data in the new container to support dating — they cannot rely solely on the manufacturer's data which was generated in a different container. The studies should include all quality attributes, not just appearance. Expiry or retest dates may need to be shortened based on the new container's properties.

Intermediaries act as information conduits between manufacturers and customers. Information to transfer: CoAs with every shipment, change notifications from manufacturer, complaint information from customers back to manufacturer, regulatory updates, specifications, stability data. The transfer must be timely — delays can cause regulatory issues or quality incidents. Intermediaries should not filter, summarize, or selectively forward information.

This is a specific implementation of traceability. When intermediaries issue their own CoAs (e.g., for convenience or after repackaging), the original manufacturer must still be identifiable. The CoA should state: 'Manufactured by: [Original Manufacturer Name and Address]'. Without this, the true source of the API becomes hidden. This clause supports regulatory traceability and quality investigations.

Regulatory authorities may contact intermediaries during inspections or investigations. Intermediaries must cooperate and provide information directly to regulators or facilitate regulator access to manufacturer information. This includes recall situations where regulators need complete distribution information quickly. Intermediaries should have procedures for regulatory interactions and appropriate training for personnel who might encounter regulators.

Supply chain transparency supports customer due diligence. Customers (drug product manufacturers) are ultimately responsible for the quality of products they use, and they need to know where their APIs come from. Intermediaries should not hide their role or the identity of the original manufacturer. Information should be available on request, not just through commercial contracts.

Intermediaries often receive complaints before the manufacturer does. They must maintain complete records and forward complaints to the manufacturer. For recalls, intermediaries must participate actively — providing their customer lists, facilitating product retrieval, communicating to their customers. Records must be complete enough to support recall effectiveness and regulatory reporting.

Intermediaries can investigate complaints related to their own activities (e.g., transport damage, repack errors, storage issues). For complaints related to product quality (assay, impurities, efficacy), investigation must involve the original manufacturer who has access to batch records and manufacturing data. Prompt forwarding enables the manufacturer to investigate thoroughly and meet their regulatory obligations.

Original manufacturers decide when to recall, but intermediaries execute critical recall steps for their portion of the supply chain. Intermediary responsibilities: notify their customers promptly, retrieve product efficiently, track recall effectiveness, report back to manufacturer with customer-level data. Procedures should be tested through mock recalls. Failure of intermediaries to execute recalls efficiently can make the entire recall ineffective.

Return handling at intermediaries follows the same principles as at manufacturers (Section 14.5). Returns must be quarantined, assessed for quality impact, and dispositioned appropriately. Quality-related returns should be forwarded (physically or with information) to the manufacturer for investigation. Returns that may indicate quality issues should not be placed back in saleable inventory without manufacturer involvement.